Table 3

Motor symptoms, disease burden, quality of life, disability and psychiatric outcome at the end of the open-label follow-up

Median score (IQR) at start open-label phaseMedian score (IQR) end of follow-upP value*
CGI-severity investigator3.0 (2.0; 4.0)2.0 (1.0; 4.0) 0.005
CGI-severity patient4.0 (4.0; 5.75)4.0 (2.0; 5.0) 0.044
VAS-disease burden patient48.0 (20.3; 71.8)28.0 (3.0; 62.0) 0.042
PMDRS-motor symptoms10.0 (5.0; 21.0)9.0 (3.0; 17.0) 0.010
SF-36-Physical component†34.4 (25.1; 48.3)40.2 (27.4; 53.6)0.058
SF-36-Mental component†52.5 (41.2; 56.9)50.0 (37.9; 55.7)0.751
ALDS-disability†87.8 (79.2; 89.5)89.1 (83.5; 89.5)0.790
BDI-Depressive symptoms†9.0 (4.0; 12.0)6.0 (3.0; 13.5)0.370
MADRS-Depressive symptoms12.0 (15.0; 18.8)10.0 (4.0; 18.0)0.205
BAI-Anxiety symptoms†11.0 (3.5; 17.0)7.0 (4.0; 16.0)0.127
LSAS-Social anxiety†10.0 (4.0; 21.5)10.0 (2.0; 16.5)0.446
OCI-Obsessive-Compulsive symptoms†4.0 (1.0; 7.0)3.0 (1.5; 5.0) 0.028
  • Bold figures indicate P values< 0.05.

  • *Wilcoxon signed-rank test for paired data.

  • †Data of n=41 patients.

  • ALDS, AMC Linear Disability Score; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CGI, Clinical Global Impression; IQR, Interquartile range; LSAS, Liebowitz Social Anxiety Scale; MADRS, Montgomery Asberg Depression Rating Scale; OCI, Obsessive Compulsive Inventory; PMDRS, Psychogenic Movement Disorder Rating Scale; SF-36, Short Form 36; VAS, Visual Analogue Scale.